The data (Figure 4) show that MH treatment dose-dependently inhibited both Bcl-2 and Bcl-XL in drug-sensitive (A549 and H1299) and drug-resistant (A549-TR) lung cancer cells (Figure 4A–C). Here, BCL2L1 is linked to lung carcinoma.